Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects
Alzheimer Disease
/ drug therapy
Animals
Catalytic Domain
Cell Line, Transformed
Coumaric Acids
/ chemical synthesis
Histone Deacetylase 6
/ antagonists & inhibitors
Histone Deacetylase Inhibitors
/ chemical synthesis
Immunologic Factors
/ chemical synthesis
Male
Melatonin
/ analogs & derivatives
Mice
Molecular Docking Simulation
Neuroprotective Agents
/ chemical synthesis
Structure-Activity Relationship
Tryptamines
/ chemical synthesis
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
08 04 2021
08 04 2021
Historique:
pubmed:
27
3
2021
medline:
8
6
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
The structures of melatonin and ferulic acid were merged into tertiary amide-based histone deacetylase 6 (HDAC6) inhibitors to develop multi-target-directed inhibitors for neurodegenerative diseases to incorporate antioxidant effects without losing affinity and selectivity at HDAC6. Structure-activity relationships led to compound
Identifiants
pubmed: 33769811
doi: 10.1021/acs.jmedchem.0c01940
doi:
Substances chimiques
Coumaric Acids
0
Histone Deacetylase Inhibitors
0
Immunologic Factors
0
Neuroprotective Agents
0
Tryptamines
0
ferulic acid
AVM951ZWST
Hdac6 protein, mouse
EC 3.5.1.98
Histone Deacetylase 6
EC 3.5.1.98
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM